COMP <GO>
APT vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Alpha Pro Tech Ltd. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: APT 3
— ABBV 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: APT
LAST: $5.55 (+1.28%) • MKT CAP: $56.6M
balance-sheet
5.59
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | APT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 38.10% | 70.20% | -32.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.70% | 29.00% | -22.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.0x | 33.3x | -24.30 | APT | /valuation <GO> |
| Free Cash Flow Yield | 3.06% | 3.47% | -0.41 | ABBV | /fcf-yield <GO> |
| Operating Margin | 6.50% | 24.60% | -18.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 5.90% | 6.90% | -1.00 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | — | 8.60% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 5.59 | 5.33 | +0.26 | APT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.6 | 65.1 | -18.52 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.1x | 113.1x | -98.00 | APT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $56.6M | $513.86B | -$513.80B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | APT REV | ABBV REV | APT GROSS % | ABBV GROSS % | APT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $59.1M | $61.16B | 38.1% | 70.2% | $1.7M | $17.82B |
| FY 2024 | $57.8M | $56.33B | 39.6% | 70.0% | $1.9M | $17.83B |
| FY 2023 | $0 | $54.32B | — | — | $8.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APT // BETA —
ABBV // BETA 1.15